Health Insurance (Quality Assurance Activity – Top End Health Service Peer Review Clinical Audits of Surgical Mortalities and Morbidities) Declaration 2021

The instrument relies on a small set of statutory and operational concepts, each defined implicitly by the Schedule and the cross‑references to the Health Insurance Act 1973.

• Quality assurance activity: The primary legal concept introduced by the instrument. Section 5 declares that “the quality assurance activity described in the Schedule” is, to the extent it relates to health services in Australia, “declared to be a quality assurance activity to which Part VC of the Health Insurance Act 1973 applies.” The Declaration therefore depends on the statutory meaning and legal consequences of “quality assurance activity” as defined and treated within Part VC of the Act. The instrument itself does not restate Part VC; it imports that statutory regime by reference.

• Scope of clinical review: The Schedule defines the substantive universe of cases to be reviewed: patient cases that result in death, or where the patient incurred complications or substantial or long‑lasting disability after discharge. The reviews will also include patients who were admitted under a surgical team but did not proceed to have an operation (Schedule, item 2). The activity also extends to reviews and analysis of operational policies, procedures or practices and clinical issues and factors contributing to events.

• Peer review participants: The Activity “involves specialist surgeons, anaesthetists and other clinicians who perform surgical operations and who provide care for patients at the Top End Health Service” (Schedule, item 2). The Schedule identifies clinician peers as the group with authorised access to identifying information for the conduct of audits.

• Outputs and governance: Clinical audit reports and recommendations must be approved by the Executive Director of Surgery TEHS and provided to the Chief Operating Officer and Executive Director, Medical Services TEHS, and circulated within the hospital (Schedule, item 2). The Activity includes monitoring of recommendations made to those executives.

• Publication and de‑identification: The Schedule lists the non‑identifying information that will be published through NT Health reporting channels (NT Health Annual Report; NT Health Clinical Quality and Patient Safety Surveillance Report; NT Audit of Surgical Mortality) and sets out discrete items that may be published: number of cases reviewed; audit of attendance numbers; percentage of eligible cases audited; summary of themes contributing to morbidity and mortality; high‑level details of particular cases; recommendations; and a description of issues raised during morbidity and mortality (M&M) meetings (Schedule, item 2, subitems (i)-(vii)).

• Information access limitation: The Schedule restricts access to identifying information to clinician peers conducting the audit activity, the Executive Director of Medical Services, the Chief Operating Officer and NT Department of Health Legal Services (Schedule, item 2, final sentence). This concept balances internal review needs against an explicit boundary on who may see identifying material.

• Legal source and lifecycle: The instrument is made under s 124X(1) of the Health Insurance Act 1973 (s 3) and is subject to repeal in accordance with s 124X(4) (s 4). Commencement mechanics are governed by s 2.

These concepts together configure the TEHS mortality and morbidity peer review as a bounded, executive‑approved, clinician‑led audit process with prescribed reporting lines, monitoring obligations and rules on publication and access to identifying data. The instrument does not elaborate on procedural detail for how audits are to be conducted, how de‑identification is to be effected, or how disputes about access are to be resolved; it focuses on designation, scope and destination of outputs.

The Declaration identifies a small, identifiable set of actors whose duties, access and decision roles are specified or implicated by the Schedule.

• Clinician peers: Specialist surgeons, anaesthetists and other clinicians who perform surgical operations and provide perioperative care within TEHS are both the subject‑matter experts conducting reviews and a class of persons who will have access to identifying information for the purposes of the audits (Schedule, item 2). They will need to participate in case reviews and M&M meetings and may discuss clinical practice and, in some circumstances, individual clinical performance.

• Patients whose care is reviewed: The activity applies to cases that result in death, or where the patient suffered complications or substantial or long‑lasting disability after discharge. The scope explicitly includes patients admitted under a surgical team who did not proceed to operation. Patients and their identifying information may therefore be involved in the audit process. The Schedule does not include a patient consent mechanism; it restricts access to identifying information to certain roles, but does not state patient rights within the instrument text.

• Executive Director of Surgery TEHS: This officer is designated as the approver of clinical audit reports and recommendations (Schedule, item 2). The Executive Director of Surgery therefore controls the release of internal reports and the formal sign‑off that triggers circulation to executive management.

• Executive Director, Medical Services TEHS and Chief Operating Officer: These two executives are explicit recipients of approved clinical audit reports and recommendations and will receive those materials for action and monitoring (Schedule, item 2). They are also named among the limited group who may access identifying information.

• NT Department of Health Legal Services: Legal Services are explicitly authorised to access identifying information arising from the Activity (Schedule, item 2). This gives legal officers a direct role in receiving case information for legal or governance purposes.

• The hospital/TEHS organisation more generally: The Schedule requires circulation of approved reports “within the hospital” and identifies NT Health reporting channels for non‑identifying publication. As such, hospital governance structures, quality and safety teams and any units charged with monitoring implementation of recommendations are affected.

• NT Health reporting units: The Schedule anticipates publication via NT Health Annual Report, NT Health Clinical Quality and Patient Safety Surveillance Report and NT Audit of Surgical Mortality. Units that compile those reports will receive summary materials arising from the activity.

The instrument does not name private practitioners outside TEHS, external auditors, coronial services, regulatory bodies or insurers as having authorised access. It also does not specify any obligations that private hospitals must follow. The boundary of authorised access is therefore inward‑facing to TEHS governance and to NT Department of Health Legal Services. The Declaration makes no express provision for family or patient representatives to access audit records, nor does it alter or create public rights to access identifying material.

The instrument itself is declaratory and prescriptive in a narrow way: it designates the TEHS peer‑review audits as a Part VC quality assurance activity and sets out duties and rights connected to report approval, circulation, monitoring and restricted access to identifying information. The Schedule contains the operative operational duties and rights.

Duties and operational obligations stated in the Schedule

• Conduct reviews and analyses: Specialist surgeons, anaesthetists and other clinicians are required by the design of the Activity to review and analyse patient cases meeting the defined criteria (cases resulting in death, complications, or substantial or long‑lasting disability; and cases admitted under surgical teams who did not proceed to operation) (Schedule, item 2). The Activity also requires review and analysis of operational policies, procedures or practices and clinical issues and factors that contribute to events.

• Identify contributing factors and make recommendations: The Activity must “identify contributing clinical factors to these events and make recommendations to the Executive Director Medical Service of the TEHS about changes or improvements in a policy, procedure or practice relating to the provision of health services to reduce the likelihood, or prevent the same or similar event from occurring again” (Schedule, item 2). That duty has two components: (1) diagnosis of contributing factors; and (2) formulation of recommendations aimed at system, policy or practice change.

• Monitor recommendations: The Activity includes “the monitoring of those recommendations.” This imposes an ongoing governance duty beyond a one‑off report: the Activity must track whether recommended changes are implemented and whether they achieve their intended effect (Schedule, item 2).

• Approve and circulate reports: Clinical audit reports and recommendations must be approved by the Executive Director of Surgery TEHS, and such approved reports must be provided to the Chief Operating Officer and Executive Director, Medical Services TEHS and circulated within the hospital (Schedule, item 2). Approval and circulation are formalised duties that vest control of report release in a named executive.

Rights and limitations stated in the Schedule

• Access rights to identifying information: The Schedule explicitly limits access to identifying information to clinician peers conducting the audit activity and to three named managerial/legal entities , the Executive Director of Medical Services, the Chief Operating Officer and NT Department of Health Legal Services (Schedule, item 2). That is a concrete right for those listed and a concrete restriction for all others.

• Publication of non‑identifying information: The Schedule permits publication of certain non‑identifying outputs arising from the Activity via named NT Health channels. The Schedule lists the specific items that may be published (Schedule, item 2, subitems (i)-(vii)). This creates a right for NT Health to publish aggregated and thematic audit outputs, but confines publication to non‑identifying material.

Matters not specified in the instrument

• The Declaration does not set out formalised procedural protections for clinicians whose individual performance “may also be discussed” (the Schedule states that clinical practice and performance of individuals may be discussed dependent on circumstances). The instrument does not describe appeals or review rights for clinicians, confidentiality obligations beyond the stated access limitations, or the process for resolving disputes over de‑identification or publication.

• The instrument does not specify consent requirements from patients, mechanisms for recording or redacting identifying information, nor does it specify exact monitoring plans such as timelines, responsible officers for monitoring, or reporting back to clinicians on implementation status.

• The Declaration does not itself create obligations for external entities such as coroners, insurers or regulators. It does not specify whether material disclosed to NT Department of Health Legal Services is subject to legal professional privilege or other evidentiary protections; nor does it set out retention or destruction schedules for identifying information.

In sum, the key duties created or made explicit by the Declaration relate to conducting and analysing peer reviews, producing and approving reports, making and monitoring recommendations, circulating results within TEHS, and restricting access to identifying data to named roles. Rights are likewise narrow: named executives and clinician peers have authorised access; NT Health has the right to publish specified non‑identifying outputs.

The instrument itself contains no express penalty provisions, sanctions regime, enforcement mechanism, or compliance fines. The text does not create offences, regulatory enforcement powers, or civil remedies. Rather, the instrument performs an administrative declaration that the TEHS peer‑review Activity is a “quality assurance activity to which Part VC of the Health Insurance Act 1973 applies” (s 5). The legal consequences that follow from that designation will therefore arise from Part VC of the Health Insurance Act 1973 and any enforcement or protection mechanisms contained in that Part. The instrument cites the statutory authority used to make the declaration (s 3: “This declaration is made under subsection 124X(1) of the Health Insurance Act 1973”) and cross‑references repeal under subsection 124X(4) (s 4), which attaches the instrument’s legal lifecycle to provisions in the Act.

Because the Declaration imports Part VC rather than restating it, readers with compliance or enforcement concerns must consult the Health Insurance Act 1973 to determine:

• whether Part VC creates evidentiary protections, civil‑law immunities, or criminal exemptions for material produced as part of the declared quality assurance activity, and if so, what the scope and limits of those protections are;

• whether Part VC imposes any reporting obligations, record‑keeping duties, or other enforceable requirements tied to designated quality assurance activities; and

• whether Part VC prescribes remedies, penalties, or enforcement mechanisms where an entity departs from the statutory requirements attached to quality assurance activities.

Within the instrument itself there is an implicit enforcement chain for the Activity’s internal governance: approved audit reports must be provided to specified executives (Executive Director of Surgery, Chief Operating Officer, Executive Director, Medical Services) and are to be circulated within the hospital; the Activity “includes the monitoring of those recommendations” (Schedule, item 2). That language establishes an internal accountability mechanism , monitoring by hospital executives , but the instrument does not establish external enforcement levers such as ministerial directions, regulatory sanctions, or penal consequences for failure to monitor or implement recommendations.

Practitioners should therefore treat this Declaration as a gateway instrument: it designates the audit activity for the statutory framework in the Act, but detailed questions about legal protections (for example, whether audit material is inadmissible in certain proceedings), enforcement of duties or penalties for non‑compliance rest in Part VC and other applicable laws. The Declaration supplies the administrative architecture (who approves reports, who receives them, who may access identifying material) but not the penal mechanics; those must be sourced from the Health Insurance Act 1973 and any other relevant Commonwealth, Territory or local laws.

The instrument explicitly interacts with the Health Insurance Act 1973 by operation of s 3 and s 5. Section 3 states the Declaration is made under subsection 124X(1) of the Act. Section 5 declares that the quality assurance activity described in the Schedule is “declared to be a quality assurance activity to which Part VC of the Health Insurance Act 1973 applies.” Those are the textual points of legal contact in the instrument.

Immediate statutory interaction

• Importation of Part VC: By declaring the Activity to be a Part VC quality assurance activity, the instrument incorporates any statutory rules, protections, immunities, exclusions, evidentiary regimes, reporting obligations, or other legal consequences that Part VC attaches to such designated activities. The Declaration does not restate those rules; it relies on the external operation of Part VC.

Interaction with privacy, confidentiality and legal processes (implicit rather than explicit)

• Publication and de‑identification: The Schedule mandates publication of specified items in non‑identifying form via NT Health reporting channels (Schedule, item 2, subitems (i)-(vii)). That interactively engages privacy and information‑handling regimes. The Declaration itself does not refer to the Privacy Act, Territory privacy law, health records legislation or common law confidentiality; however, the practice of publishing non‑identifying outputs and restricting identifying information to a named set of persons interacts operationally with those regimes in practice. The instrument restricts access to identifying information to clinician peers, Executive Director of Medical Services, Chief Operating Officer and NT Department of Health Legal Services, which creates an internal control layer. How that control layer aligns with or is constrained by privacy laws and obligations must be tested against those laws, which are not reproduced in the instrument.

• Legal counsel access: NT Department of Health Legal Services is explicitly authorised to access identifying information. That creates a link between the Activity and legal advice, risk management, or potential litigation processes managed by Legal Services. The instrument does not specify whether material seen by Legal Services is subject to legal professional privilege or other protections.

Interaction with hospital governance and reporting obligations

• Internal circulation and monitoring: Approved reports are to be provided to and circulated by named executives and monitored. That places the Activity within TEHS governance and quality improvement frameworks. It also links the Activity to NT Health reporting outputs (NT Health Annual Report, Clinical Quality and Patient Safety Surveillance Report, NT Audit of Surgical Mortality), which may have their own legislative or policy drivers.

Matters not addressed by the instrument but relevant to interaction with other laws

• The Declaration does not address coronial obligations or statutory reporting to external regulators. It does not withdraw or override obligations to report deaths or adverse events to coroners, statutory notification schemes, professional regulators, or insurers. The instrument is silent on whether or how audit material might be disclosed to such bodies, or whether Part VC status affects disclosure obligations. Those questions fall to the interaction between the Health Insurance Act 1973, Territory coronial and reporting laws, professional regulation regimes, and common law duties of disclosure.

• The instrument does not address employment law consequences that may arise if individual clinical performance is discussed. Because the Schedule states individual clinical performance “may also be discussed” depending on the circumstances, that raises potential intersections with employment, disciplinary, and professional conduct procedures; the instrument does not purport to displace those legal processes.

In short, the Declaration is a specific statutory cross‑reference: it brings the TEHS peer review within Part VC of the Health Insurance Act 1973, and it imposes internal requirements about approval, circulation, monitoring and restricted access. The broader legal interactions , privacy, coronial, professional discipline, evidentiary admissibility and employment law , are not resolved by the instrument and require consultation of the Act and other applicable laws.

The instrument contains a commencement table (s 2) and a note that the table “relates only to the provisions of this instrument as originally made” and “will not be amended to deal with any later amendments of this instrument” (s 2 note). The commencement table states that the whole instrument commences “The day after this instrument is registered” (s 2 table). The instrument does not contain any textual amendments, schedules of amendment, or subsequent modifying instruments within the text provided.

Specific points from the instrument about amendment and repeal

• Commencement: The whole instrument commenced the day after registration (s 2). No other staggered commencement provisions are present.

• Repeal: The instrument is repealed when it ceases to be in force in accordance with subsection 124X(4) of the Health Insurance Act 1973 (s 4). The instrument therefore ties its own repeal to a provision in the parent Act rather than prescribing a fixed sunset within the instrument.

• Editorial note on Column 3: Section 2(2) expressly states that any information in column 3 of the commencement table “is not part of this instrument” and “may be inserted in this column, or information in it may be edited, in any published version of this instrument.” That reflects an administrative practice about publication metadata and does not affect the legal content of the instrument.

What the instrument does not say about amendment

• There is no express power within the text of the instrument to vary the Schedule, to extend the declared activity beyond TEHS, or to add further publication categories. Any amendment to the Declaration, including substitution or expansion of the declared activity, would need to be made pursuant to the parent Act (for example, by further exercise of the power in s 124X(1) of the Health Insurance Act 1973) and be properly registered.

• There is no transitional or saving provision attached to the instrument itself addressing how cases in progress at commencement are to be treated.

For users tracking statutory instruments, the immediate practical consequence is that the Declaration has a clear, singular commencement and a repeal mechanism tied to the parent Act. Any changes to the declared scope or any extension of the quality assurance designation would require a fresh declaration or an amendment made under the authorising statutory power.

The instrument, as presented, contains no litigation history. It does not cite any judicial decisions, and it does not record any legal challenges, stays, or orders. The Schedule refers to internal governance and reporting arrangements but does not record litigation or dispute resolution outcomes.

Practical implications of the absence of litigation material in the instrument

• Absence of precedential interpretation: Because the instrument does not contain or refer to any case law, there is no judicial interpretation of the declared terms recorded in the instrument itself. Any questions about the operation of Part VC as applied to this declared activity would need to be addressed by reference to the Health Insurance Act 1973, any case law interpreting Part VC, and any administrative guidance issued by the relevant health or legal authorities. The instrument does not provide that guidance.

• Potential for later litigation: The Schedule contemplates discussion of individual clinical practice and performance “dependent on the circumstances of the event.” That creates circumstances in which clinicians might seek legal advice or challenge how the Activity handles identifying information, publication, or its interaction with employment or disciplinary procedures. The instrument does not pre‑empt or constrain such potential litigation.

• Role of NT Department of Health Legal Services: The Schedule specifically authorises NT Department of Health Legal Services to access identifying information. That is an operational allocation of information to in‑house counsel which may affect discovery, privilege and disclosure in future litigation. The instrument does not state whether such material is automatically privileged or subject to other protections.

In short, the instrument itself contains no litigation history and gives no judicially shaped interpretation. Questions about legal effect, evidentiary admissibility, confidentiality and rights in potential disputes will depend on external legislation, administrative policy and any later litigation that interprets the Act and this Declaration in practice.

The Schedule contains several tightly framed operational choices and omissions that create practical risks and compliance traps for implementers. The following items are drawn from the instrument text and identify concrete implementation points that can produce unintended consequences if not managed explicitly.

1. Scope includes non‑operated admissions: The Activity explicitly covers “patients admitted under the surgical team but who did not proceed to have an operation” (Schedule, item 2). That expands review coverage beyond completed surgical procedures to include preoperative decision‑making, cancellations, and admissions management. Implementers must ensure case capture and criteria include these patients; failure to do so could produce incomplete auditing or retrospective exclusions.

2. Individual performance may be discussed: The Schedule states that “dependent on the circumstances of the event, the clinical practice and performance of individuals may also be discussed.” The instrument does not set out procedural safeguards for clinicians whose performance is discussed. There is an implementation risk if clinicians perceive no clear process for notification, representation, or recourse. Employers should anticipate employment, professional regulation and natural justice implications and align audit procedure with existing disciplinary policies.

3. Narrow authorised access to identifying information: Access to identifying information is limited to clinician peers conducting the audit activity, the Executive Director of Medical Services, the Chief Operating Officer and NT Department of Health Legal Services (Schedule, item 2). That restriction protects patient privacy in part but creates practical issues: if other units (risk, claims management, external investigators or regulators) request identifying information, the Schedule does not authorise disclosure. Implementers must design an information‑request protocol to manage external demands consistent with statutory obligations and record the legal basis for any disclosure outside the authorised list.

4. Publication is defined but not operationalised: The Schedule lists seven specific items that may be published in non‑identifying form (Schedule, item 2, subitems (i)-(vii)). The instrument does not define “non‑identifying” nor set out de‑identification standards, re‑identification risk assessment, redaction procedures, or approval chains for publication. That omission leaves implementers to decide how to de‑identify case information; inadequate de‑identification may expose patients to privacy breaches or complaints.

5. Reporting and monitoring duties without timelines: The Activity “includes the monitoring of those recommendations” but no timelines, reporting frequency, responsible officers or escalation pathways are prescribed. This creates a risk that recommendations are generated but not systematically implemented or tracked. Implementers should design a monitoring regime with clear owners and deadlines.

6. Interaction with Part VC left implicit: The Declaration applies Part VC of the Health Insurance Act 1973 to the Activity (s 5) but does not summarise what that entails. Practitioners should not assume protections or exclusions; they must read Part VC to determine evidentiary treatment, admissibility in proceedings, or other statutory effects.

7. No patient consent mention: The instrument does not state whether patient consent is required or how patients will be informed that their cases may be subject to peer review. That is a policy gap with potential privacy and reputational consequences. Implementers should consult applicable privacy law and consider notification or consent protocols where appropriate.

8. Legal Services access without clarity on privilege: NT Department of Health Legal Services is authorised to access identifying information. The instrument does not state whether such access is intended to create or preserve legal professional privilege, or whether it may be used defensively or for claims management. That raises evidentiary questions for future litigation.

9. Geographic limitation phrasing: Section 5 declares the Activity to be a quality assurance activity “to the extent that the quality assurance activity relates to health services provided in Australia.” That phrase is likely precautionary, but implementers should confirm whether any cross‑jurisdictional matters or telehealth cases outside Australia present edge‑cases for the declared status.

10. Column 3 in commencement table is non‑binding: Section 2(2) says information in column 3 of the commencement table “is not part of this instrument” and may be edited in published versions. Implementers and lawyers should not treat explanatory or editorial footnotes in published copies as authoritative legal content.

These are operational and legal practicalities arising directly from the instrument text. Each one points to a concrete implementation decision: how to capture cases, how to handle individual performance discussions, how to de‑identify data, how to monitor recommendations, and how to reconcile internal access controls with external disclosure obligations. The instrument confers designation and internal governance markers; it leaves a number of procedural and compliance specifics to local policy and to the interaction with Part VC and other laws.

Compliance requires implementing the operational structures signalled in the Schedule, ensuring authorised access rules are respected, and aligning the Activity with the statutory consequences of being a Part VC quality assurance activity. The instrument prescribes the core elements; the following practical steps translate the Schedule into an implementable compliance checklist.

1. Confirm commencement and legal basis

• Record the commencement date. The instrument commenced the day after registration (s 2). Ensure the Activity’s internal timelines, versioning and record‑keeping reflect that legal start date.
• Record the statutory authority for the declaration (s 3: made under subsection 124X(1) of the Health Insurance Act 1973) and the repeal mechanism (s 4: repealed in accordance with subsection 124X(4)). Maintain a legal file that includes the Declaration and a note to consult Part VC of the Act for substantive legal effects.

2. Define and capture the cases in scope

• Implement case‑capture criteria to include: (a) patient cases resulting in death; (b) cases resulting in complications or substantial or long‑lasting disability after discharge; and (c) patients admitted under a surgical team who did not proceed to operation (Schedule, item 2).
• Ensure clinical records systems flag such cases for audit review and maintain an audit log of all cases considered and the outcome of the peer review.

3. Assemble the authorized peer review panel

• Use specialist surgeons, anaesthetists and other clinicians who perform surgical operations at TEHS as peer reviewers (Schedule, item 2).
• Maintain written role descriptions and confidentiality agreements for clinician peers reflecting the access limitation to identifying information.

4. Control access to identifying information

• Implement strict access controls so that identifying information is available only to clinician peers conducting the audit activity, the Executive Director of Medical Services, the Chief Operating Officer and NT Department of Health Legal Services (Schedule, item 2).
• Maintain an access register recording who viewed identifying material, for what purpose, and when. Ensure audit trails are preserved in line with record‑keeping policies.

5. Approve and circulate reports per governance lines

• Ensure clinical audit reports and recommendations are formally approved by the Executive Director of Surgery TEHS before distribution (Schedule, item 2).
• After approval, provide reports to the Chief Operating Officer and Executive Director, Medical Services TEHS and circulate within the hospital. Designate responsible officers for ensuring timely distribution.

6. Monitor implementation of recommendations

• Set up a monitoring framework for recommendations: assign owners for each recommendation, set due dates, record evidence of implementation, and schedule periodic reporting to governance committees.
• Document monitoring outcomes and include them in governance minutes or quality and safety reports.

7. Publish non‑identifying outputs in accordance with the Schedule

• Prepare and publish only the specified non‑identifying information: number of cases reviewed; audit of attendance numbers at the TEHS Activity; percentage of eligible cases audited; summary of themes that contribute to morbidity and mortality; high‑level details of particular cases; recommendations made; and a description of issues raised during M&M meetings (Schedule, item 2, subitems (i)-(vii)).
• Develop and document de‑identification standards that operationalise “non‑identifying,” including assessment of re‑identification risks. Ensure any published material is reviewed by an authorised officer (for example, the Executive Director of Surgery or Legal Services) before public release.

8. Handle individual performance discussions carefully

• Where individual clinical practice or performance is discussed, ensure processes align with employment and professional conduct frameworks. Inform clinicians of the possibility of such discussion and provide access to representation or appeal where internal disciplinary processes may be implicated.
• Coordinate with Human Resources and Legal Services to establish whether and how peer review findings that touch on individual performance should be escalated or referred to formal processes.

9. Align with privacy and legal obligations

• Consult applicable privacy legislation and health records law to ensure data handling, de‑identification, retention and disclosure practices meet statutory obligations. Although the Declaration limits access to identifying information, it does not displace privacy law obligations.
• Coordinate with NT Department of Health Legal Services for guidance on privilege, disclosure, and potential external demands for audit records (for example, subpoenas, regulatory requests, coronial inquiries).

10. Document policies and training

• Produce a written policy describing the TEHS peer review Activity: scope, membership, access controls, report approval and circulation process, publication rules, monitoring framework, and the role of Legal Services.
• Train participating clinicians and administrative staff in the policy, emphasising access restrictions, de‑identification procedures, and reporting timelines.

11. Maintain an audit trail for legal and governance purposes

• Keep contemporaneous minutes of M&M meetings, redaction logs for any published material, records of approvals by the Executive Director of Surgery, records of monitoring actions, and the access register for identifying information. This will support internal governance and any legal queries about adherence to the Declaration and to Part VC of the Health Insurance Act 1973.

12. Review interaction with Part VC and other laws

• Obtain legal advice on the consequences of having the Activity treated as a Part VC quality assurance activity, including evidentiary effects, admissibility in court or regulatory processes, and any statutory protections or obligations that Part VC confers.
• Review how the Activity aligns with coronial obligations, mandatory incident reporting schemes, professional regulation requirements, and insurance reporting obligations, and document any necessary cross‑referral protocols.

Following these steps will translate the Declaration’s limited prescriptive content into an operationally compliant peer review program that respects the Schedule’s access limitations, governance approvals and publication parameters while aligning with applicable legal duties.